Exhibit 99.1
PRESS RELEASE
Cellectis S.A. Reports Results from Annual General Meeting
Held on June 26, 2018
June 27, 2018 (4:30pm CEST) – New York (N.Y.) –Cellectis S.A. Annual General Meeting (Euronext Growth: ALCLS – Nasdaq: CLLS) was held on Tuesday, June 26, 2018 in Paris, at its head office.
At the meeting, during which more than 64% of voting rights were exercised, all the resolutions for which the management recommended a vote in favor, were adopted.
The resolutions adopted by Cellectis’ shareholders included notably:
• | Approval of the annual financial statements for the financial year ended December 31, 2017; |
• | Approval of the consolidated financial statements for the financial year ended December 31, 2017. |
• | Renewal of the term of office of Director of Mr. André Choulika, Mr. David Sourdive and Mr. Alain Godard; |
• | Renewal of the term office of Ernst & Young et Autres, and J.M.H. Conseil as Company’s Statutory Auditors. |
The full results of the vote can be examined on the company’s websitewww.cellectis.com/en/investors/general-meetings/
About Cellectis
Cellectis is a clinical-stage biopharmaceutical company focused on developing a new generation of cancer immunotherapies based on gene-editedT-cells (UCART). By capitalizing on its 18 years of expertise in gene editing – built on its flagship TALEN® technology and pioneering electroporation system PulseAgile – Cellectis uses the power of the immune system to target and eradicate cancer cells.
Using its life-science-focused, pioneering genome engineering technologies, Cellectis’ goal is to create innovative products in multiple fields and with various target markets.
Cellectis is listed on the Nasdaq market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). To find out more about us, visit our website:www.cellectis.com
Talking about gene editing? We do it. TALEN® is a registered trademark owned by Cellectis.
For further information, please contact:
Media contacts:
Jennifer Moore, VP of Communications,917-580-1088,media@cellectis.com
Caitlin Kasunich, KCSA Strategic Communications,212-896-1241,ckasunich@kcsa.com
IR contact:
Simon Harnest, VP of Corporate Strategy and Finance,646-385-9008,simon.harnest@cellectis.com
###